Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Dermalux

Also known as: dermalux, dermalux flex, dermalux tri-wave

Dermalux is a UK-made family of LED phototherapy devices from Aesthetic Technology Ltd. Its systems deliver blue 415 nm, red 633 nm and near-infrared 830 nm light, singly or in combination. Brand-specific clinical evidence is sparse; most wavelength evidence comes from other devices.

Evidence status

Manufacturer-supported

Brand-specific evidence is limited to one 20-patient open-label comparison, in which both treatments improved acne but IPL performed better on the efficacy endpoint. No registered Dermalux clinical study was found, and its four FDA clearance files rely on bench testing or equivalence rather than clinical performance data. Much supporting wavelength evidence comes from other manufacturers' devices, while Dermalux's own website says several marketed uses fall outside the CE scope it describes.

What Dermalux is, and the types available#

Dermalux is a brand of Aesthetic Technology Ltd, a UK medical-device manufacturer incorporated in 2012 and based in Warrington. The same company and address appear in Companies House, MHRA and FDA records.[6, 1, 4, 5, 8]

The current professional range comprises the floor-standing four-panel Tri-Wave MD, the tabletop three-panel Compact Lite and the portable flexible-array Flex MD. FDA additionally cleared Tri-Wave MD MKII and Compact MD models in 2024.[8, 4]

All use blue 415 nm, red 633 nm and near-infrared 830 nm. FDA filings give a wavelength tolerance of ±5 nm; current manufacturer material gives ±2 nm. Shared wavelengths do not mean shared output. FDA-declared Tri-Wave MD maxima are 105 mW/cm² red, 40 blue and 55 near-infrared, with standard doses of 126, 48 and 66 J/cm² respectively over 792 cm². The manufacturer's headline 200 mW/cm² and 240 J/cm² figures are the arithmetic totals of all three channels, not a per-wavelength output.[1, 2, 4, 8][1]

The Flex MD is substantially lower-output: 11.5 mW/cm² red, 5.52 blue and 5.5 near-infrared, with standard doses of 20, 10 and 10 J/cm². That is 40 J/cm² combined against 240 J/cm² for Tri-Wave MD. “Portable Tri-Wave” is therefore not an adequate technical description.[2, 1, 8]i

Use of Dermalux in aesthetic practice#

The manufacturer describes Tri-Wave MD and Flex MD as Class IIa devices and associates them with CE 2797; the public certificate itself could not be located in the public material examined. The product pages do not show a UKCA mark. CE-marked EU MDR devices remain accepted in Great Britain under transitional recognition to 30 June 2030, subject to policy change; Northern Ireland follows EU rules.[8, 4, 7][no source found]

The Compact Lite is different. The manufacturer states that it is an electrical, non-medical device outside CE 2797 scope. That affects intended purpose, claims, consent and insurance even though it shares the brand and wavelengths.[8]

MHRA registration is a market-notification duty, not approval of efficacy or indications. Aesthetic Technology's entry records a Class IIa blue/red/infrared phototherapy lamp; it does not create an “MHRA-approved indication”. Similarly, the FDA badge on UK marketing has no UK legal effect. FDA 510(k) is a US substantial-equivalence route, not proof of efficacy.[1, 3, 7]i

The formally stated US indications are narrow: 415 nm for moderate inflammatory acne vulgaris; 633 nm for superficial benign vascular and pigmented lesions; and 830 nm for temporary minor muscle and joint pain relief, stiffness or spasm and temporary local-circulation increase. Flex MD additionally includes periorbital and full-face wrinkles. UK advertising must be supported under CAP rules and remain within the actual device's certified scope.[8, 14][1, 2, 3, 4]

Contraindications and cautions#

The current IFU for the exact Dermalux model is the controlling source for contraindications, eye protection, medicine- or condition-related photosensitivity, positioning and exposure. Because outputs differ by approximately an order of magnitude between Tri-Wave MD and Flex MD, suitability and dose cannot be transferred by brand name alone.[1, 2, 8]

The device identity must be confirmed before treatment. The manufacturer says Compact Lite is outside CE 2797 and describes Tri-Wave MD and Flex MD as Class IIa; its marketed indication lists do not match the certification scope stated in its own footnotes.[8] A clinic unable to identify the build, conformity documentation, current IFU and covered intended use should not treat.

Medical conditions, suspicious lesions, active infection, a known photosensitivity disorder or medicine, and any eye-safety concern require assessment against the manufacturer documentation and referral where necessary. Skinipedia does not substitute a generic LED contraindication list for the current model-specific document.

Clinical uses and the evidence behind them#

Acne

Blue 415 nm for moderate inflammatory acne is a formally stated indication.[1, 2, 3, 4] The highest-tier evidence, however, concerns light therapies as a class rather than Dermalux. A Cochrane review of 71 trials and 4,211 participants found high-quality evidence lacking, graded the key outcome very low quality and reported that two thirds of included studies were industry-sponsored.[10]

No Dermalux-specific acne clinical trial is available. This leaves a stated regulatory indication without brand-specific outcome data sufficient to quantify effect.

The manufacturer's science page extends beyond that narrow indication, claiming that blue 415 nm treats all grades of acne, targets certain viruses and has mood-enhancing benefits. Those claims exceed the moderate-inflammatory-acne wording in the regulatory filings and the accessible evidence base.[8, 1, 10]i

Redness and facial hypervascularisation

The sole PubMed-indexed Dermalux clinical study was an open-label, non-randomised proof-of-concept comparison in 20 patients, ten per arm. All Dermalux-treated patients showed moderate improvement in haemoglobin hyperconcentration and 70% reported no pain. IPL produced marked improvement in 90% but severe pain in all participants. The balanced description is gentler and better tolerated, but less effective in this small study.[9][9]

The study's independence cannot be confirmed. Both authors worked at a commercial laser clinic, the PubMed record contains no funding or conflict statement, and full text was unavailable; the manufacturer uses the paper commercially.[9]

Wrinkles and ageing skin

Flex MD carries a US wrinkles indication, but the manufacturer's CE footnote excludes ageing skin for both Tri-Wave MD and Flex MD.[2, 3, 4, 8] The Tri-Wave MD red and near-infrared standard doses—126 and 66 J/cm²—match those used in a foundational 2005 Omnilux study. That suggests adoption of parameters supported on a competitor device, not a Dermalux clinical replication.[1, 11]i

Wound support and other uses

The only NHS report in the evidence base is a 2022 conference abstract describing Tri-Wave MD as an adjunct to hidradenitis surgery at Bedford Hospital. It reported sufficient wound improvement but gave no participant number, comparator, outcome measure or statistics. Elsewhere, Dermalux appears incidentally—for example after hair transplantation in a five-patient case series with no LED-specific outcome or parameters.[12][13]

No registered clinical trial for Dermalux or Aesthetic Technology Ltd is available. Exactly one indexed clinical paper names a Dermalux device.[9][no source found]

Selecting a Dermalux device#

Selection begins with regulatory identity, certified indication, wavelength, irradiance, dose, treatment area and geometry. A combined headline number obscures the contribution of each wavelength, and Tri-Wave MD and Flex MD cannot be compared as though they deliver the same exposure.[1, 2, 8]

The manufacturer's own product pages disclose a material certification gap. For Tri-Wave MD, ageing skin, inflammatory skin, skin tone and redness are outside CE 2797. For Flex MD, ageing skin, inflammatory skin, pigmentation and redness are outside. The exclusions differ by device, so the exact footnote matters more than a range-wide claim.[8]

The 2021 Flex MD FDA filing reports the manufacturer's protocol as three to four sessions weekly for four weeks for acne and wrinkles, and three weekly for pain; filings list session ranges of 1–20 minutes for Tri-Wave MD and 1–30 minutes for Flex MD, with a 2.5 cm minimum working distance for Tri-Wave MD. These are product-specific manufacturer/regulatory instructions, not a generic MSTA LED protocol. The current IFU supplied for the installed model and market governs.[3, 1, 8]

Adverse effects and their management#

Expected responses

The single clinical study found Dermalux better tolerated than IPL, with 70% reporting no pain.[9] A small open-label comparison cannot define the full adverse-event rate, especially across different wavelengths, outputs, indications and phototypes.

Light and heat exposure

Unexpected pain, heat, erythema, visual symptoms, headache, a pigmentary change or worsening of the treated condition requires exposure to stop and the device instructions to be followed. Persistent or severe symptoms require medical assessment.

Scope and labelling failures

Using a non-medical Compact Lite as though it shares the Tri-Wave MD's Class IIa status, or advertising a manufacturer-disclosed non-certified indication without independent substantiation, creates regulatory and consent risk even before a physical adverse event occurs.[8, 14]

No clinical data were submitted for any Dermalux FDA clearance. Three summaries say “Animal: No studies were performed. Clinical: No studies were performed”; the fourth gives no test summary. All relied on bench standards and substantial equivalence.[1, 2, 3] Clearance therefore cannot be used as an adverse-event denominator or evidence that a cosmetic use has been clinically tested.

Referral and scope boundaries#

Any lesion requiring diagnosis, inflammatory acne needing medical treatment, suspected photosensitive disorder or reaction, active infection, visual disturbance or persistent post-treatment change belongs to a clinician rather than further LED exposure.

Clinics using Dermalux for medical conditions must distinguish device certification from professional scope. A device indication does not diagnose the condition or credential the operator. Claims to treat disease engage device status, advertising rules, competence and insurance.[8, 14]i

A device-related serious incident follows the manufacturer's vigilance pathway and the MHRA Yellow Card scheme where applicable. Local-authority requirements for light-based treatment vary and must be checked locally.

Mechanism of action#

LED devices deliver non-coherent light at defined wavelength bands. Tissue response depends on wavelength, irradiance, fluence, exposure time, distance and geometry; the wavelength alone is not a dose.

Blue 415 nm is used for inflammatory acne, red 633 nm for superficial vascular or pigmented applications, and near-infrared 830 nm for deeper non-visual exposure and temporary pain or circulation indications in US filings.[1, 2, 3, 4] The biological literature for these wavelengths includes studies on other brands, particularly Omnilux. Matching a wavelength or even a nominal fluence does not establish that two arrays deliver the same field or clinical outcome.

Commonly misstated claims#

“Dermalux is MHRA approved.”

MHRA registers devices placed on the GB market; it does not approve their efficacy or record a set of “MHRA-approved indications”.

Supported statement: Aesthetic Technology Ltd has an MHRA registration for a Class IIa phototherapy lamp; conformity assessment and indication scope sit elsewhere.

“FDA clearance proves Dermalux works.”

Every Dermalux 510(k) relied on bench standards and substantial equivalence; three explicitly say no animal or clinical studies were performed, and the fourth reports no clinical test.[1, 2, 3]

Supported statement: Dermalux devices are FDA-cleared for stated US uses without brand-specific clinical performance studies in the clearance files.

“The whole range is medical-grade.”

The manufacturer states that Compact Lite is a non-medical electrical device outside CE 2797, while Tri-Wave MD and Flex MD are Class IIa devices.[8]

Supported statement: regulatory status is model-specific; the Dermalux brand spans medical and non-medical devices.

“Dermalux has extensive clinical research.”

One 20-person non-randomised indexed study names the device, and no registered Dermalux trial is available.[9]

Supported statement: the wavelengths have a wider cross-device literature, while Dermalux-specific clinical evidence is sparse and mostly regulatory or engineering documentation.

Areas of remaining uncertainty#

  • Whether the single Madrid study received manufacturer support; without a retrievable disclosure, its independence remains unestablished.[9]
  • The exact current CE 2797 certificate wording; without the public certificate, the manufacturer's footnotes are the available scope summary.[8]
  • Why Flex MD's marketed combined irradiance does not reconcile with the sum of FDA per-channel values; until explained, comparison should use source-specific figures.
  • Whether Tri-Wave MD MKII output is identical to the original model; without a published updated table, legacy specifications should not be assumed.
  • How long CE recognition will remain the GB route; because policy may change before 2030, current GOV.UK guidance should be checked before relying on the date.[7]

Frequently asked questions#

Is Dermalux MHRA approved?

No. The MHRA registers medical devices; registration is not an efficacy approval.

Are all Dermalux devices medical devices?

No. Tri-Wave MD and Flex MD are Class IIa; Compact Lite is explicitly non-medical.[8]

Is the 200 mW/cm² claim one wavelength?

No. For Tri-Wave MD it is the combined total of 105 red, 40 blue and 55 near-infrared mW/cm².[1, 8]i

Is Dermalux proven for acne?

Blue-light acne evidence exists across devices, but Cochrane rated the key evidence very low quality and no Dermalux-specific acne trial is available.[10]

Which schedule applies?

The current IFU for the exact model and indication governs. A schedule from the Flex MD FDA filing is not a universal protocol for Tri-Wave MD, Compact Lite or another LED platform.[1, 3, 8]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. US Food and Drug Administration. 510(k) Premarket Notification K200659, Dermalux Tri-Wave MD, Aesthetic Technology Ltd. Substantially equivalent determination 9 May 2020.Tier 1Supports: Full document read. Applicant: Aesthetic Technology Ltd., 211 Europa Blvd., Warrington, Cheshire WA5 7TN, United Kingdom. Regulation 21 CFR 878.4810, Regulatory Class II, Product Code GEX. Predicate: 'Phototherapy System; K190938; Shanghai Apolo Medical Technology Co, Ltd.' Device description: 'floor standing Class II medical device which emits specific wavelengths of low level, narrow band light... The wavelengths used in the Tri-Wave MD system are Blue 415nm, Red 633nm and Near Infrared 830nm.' Indications for Use verbatim: 'The blue light (415nm wavelength) is generally indicated to treat dermatological conditions and specifically indicated to treat moderate inflammatory acne vulgaris. The red light (633nm wavelength) is generally indicated for treatment of superficial, benign, vascular and pigmented lesions. The near-infrared light (830nm wavelength) is generally indicated for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation where applied.' Specification table: wavelengths Red 633nm±5nm, Blue 415nm±5nm, NIR 830nm±5nm. Maximum power density Red 105 mW/cm2, Blue 40 mW/cm2, NIR 55 mW/cm2. Standard dose Red 126 J/cm2, Blue 48 J/cm2, NIR 66 J/cm2. Adjustable dose range Red 1-126, Blue 1-48, NIR 1-66, Red/IR 1-192, Blue/IR 1-114, Blue/Red 1-174 J/cm2. Treatment area 792 cm2. Treatment time up to 20 minutes. 120 LEDs per colour per panel, 480 per colour per unit, 1440 LEDs total. Working distance 2.5cm minimum. Performance testing section lists bench and consensus-standard testing (IEC 60601-1, 60601-1-2, 62304, 62471, 60601-2-57, 62366-1, 60601-1-6) then states verbatim: 'Animal: No studies were performed. Clinical: No studies were performed.' SCOPE LIMIT: this is a US market-authorisation document with no UK legal effect, and 510(k) is a substantial-equivalence finding, not an efficacy determination.Funding / interest: Regulatory submission authored by the manufacturer, Aesthetic Technology Ltd (contact: Dale Needham). Not independent.
  2. US Food and Drug Administration. 510(k) Premarket Notification K202028, Dermalux Flex MD Phototherapy System, Aesthetic Technology Ltd. Substantially equivalent determination 16 December 2020. 510(k) Summary prepared 11 December 2020.Tier 1Supports: Full document read. Regulation 21 CFR 878.4810 and 890.5500, Class II, Product Codes ILY, OLP, OHS. Predicates: 'Biophotas Celluma 3 Phototherapy System; K152280 and K171323, Biophotas Inc.; Rejuvalite MD; K133896, Trophy Skin Inc. and Opera Lebody; K201107, GTG Wellness Co. Ltd.' Indications for Use verbatim: 'The Dermalux Flex MD is intended to deliver heat in the IR spectrum to provide topical heating for the purpose of elevating tissue temperature; for the temporary relief of minor muscle and joint pain, arthritis and muscle spasm; relieving stiffness; promoting the relaxation of muscle tissue; and to temporarily increase local blood circulation. The blue spectrum light is intended to reduce mild to moderate inflammatory acne vulgaris. The Dermalux Flex MD is intended to emit energy in the red and infrared spectrum for use in dermatology for the treatment of periorbital and full face wrinkles.' Wavelengths Red 633nm±5nm, Blue 415nm±5nm, NIR 830nm±5nm. Output power Red 11.5 mW/cm2, Blue 5.52 mW/cm2, NIR 5.5 mW/cm2. Standard dose Red 20 J/cm2, Blue 10 J/cm2, NIR 10 J/cm2. Treatment area 792 cm2, treatment time up to 30 minutes. Use: 'Rx' (prescription), versus 'OTC' for all three predicates. Manufacturer's own reconciliation of the large irradiance gap versus predicates, verbatim: 'Apparent differences in output power and standard dose do not impact safety and effectiveness because the amount of energy delivered to the skin is similar due to differences in treatment duration and distance from the LED source.' Performance testing states verbatim: 'Animal: No studies were performed. Clinical: No studies were performed.' SCOPE LIMIT: US only; substantial-equivalence finding, not efficacy.Funding / interest: Regulatory submission authored by the manufacturer, Aesthetic Technology Ltd. Not independent.
  3. US Food and Drug Administration. 510(k) Premarket Notification K212275, Dermalux Flex MD Phototherapy System, Aesthetic Technology Ltd. Substantially equivalent determination 18 November 2021.Tier 1Supports: Full document read. Class II, Product Codes OLP, OHS, ILY. Primary predicate is the company's own earlier Flex MD (K202028); secondary predicate Flexible LED Light Therapy Model HK209 (K200983, Guangzhou GLOOMED). Omnilux CLEAR (K210948) and Biophotas Celluma3 (K152280) 'are cited as reference devices for the purpose of establishing labeling equivalence' — i.e. the labelling was benchmarked against competitor devices. Indications for use identical to K202028. The material change is the use category: subject device 'OTC' versus predicate K202028 'Rx'. Conclusion verbatim: 'The Dermalux Flex MD is technologically identical to the predicate device cleared under K202028, intended for over-the-counter use.' TREATMENT PROTOCOL — this document is the only FDA source stating one, in the comparison table row 'Treatment protocol (Treatment time)': 'Acne and Wrinkles: 3-4x weekly; 4 wks. Pain relief: 3x weekly'. Performance testing states verbatim: 'Animal: No studies were performed. Clinical: No studies were performed.' SCOPE LIMIT: US only.Funding / interest: Regulatory submission authored by the manufacturer, Aesthetic Technology Ltd. Not independent.
  4. US Food and Drug Administration. 510(k) Premarket Notification K240222, Dermalux Tri-Wave MD MK II and Dermalux Compact MD, Aesthetic Technology Ltd. Substantially equivalent determination 4 June 2024.Tier 1Supports: Full document read. Applicant address updated to 'Unit 211 Europa Boulevard Warrington Cheshire WA5 7TN United Kingdom'. Predicate is the company's own Dermalux Tri-Wave MD (K200659). Product codes GEX, ILY; regulation 878.4810. Device description states the EU class explicitly, verbatim: 'The Dermalux Tri-Wave MD MK II & Dermalux Compact MD is a Medical Device (MDR Class IIa, FDA Class II) which emits specific wavelengths of low level, narrow band light for the treatment of certain aesthetic, dermatological and medical indications. The wavelengths used in the Tri-Wave MD MK II & Compact MD systems are Blue 415nm, Red 633nm and Near Infrared 830nm.' Range structure verbatim: 'The Dermalux professional use family consists of the Tri-Wave MD MKII; a floor standing unit with 4 pod treatment head, Compact MD; desk mounted unit with a 3 pod treatment head.' Indications identical to K200659 (415nm moderate inflammatory acne vulgaris; 633nm superficial benign vascular and pigmented lesions; 830nm temporary relief of minor muscle and joint pain etc.). Also states, verbatim: 'The Dermalux systems are not used to make measurements of any sort, or to draw any conclusions regarding the indication to treat. The equipment does not require checks on the light output as the LEDs do not dim with age to any practical extent.' Note this US clearance names a 'Compact MD' as a medical device, which is a different designation from the 'Compact Lite' the manufacturer currently markets in the UK as non-medical. SCOPE LIMIT: US only.Funding / interest: Regulatory submission authored by the manufacturer, Aesthetic Technology Ltd (contact: Mr Martin Hodgson, martin.h@dermaluxled.com). Not independent.
  5. Medicines and Healthcare products Regulatory Agency. Public Access Registration Database records for Aesthetic Technology Ltd under GMDN 62202, 'Blue/red/infrared phototherapy lamp'. Accessed 1 August 2026.Tier 1Supports: Queried directly against the PARD endpoints. The manufacturer record names Aesthetic Technology Ltd at Unit 211 Europa Boulevard, Warrington, Cheshire, WA5 7TN, account 8927. A manufacturer search returns two Class IIa device records under GMDN 62202, 'Blue/red/infrared phototherapy lamp': DEVICE_ID 49623, with trade name 'Dermalux', and DEVICE_ID 212634, with trade name 'Flex MD (CB)'. Neither record contains indications, wavelengths, doses or an efficacy assessment. MHRA registration is a market-notification duty, not an approval.
  6. Companies House. AESTHETIC TECHNOLOGY LTD, company number 08339881. Accessed 1 August 2026.Tier 1Supports: Verified directly. Company name AESTHETIC TECHNOLOGY LTD; company number 08339881; registered office '211 Europa Boulevard, Westbrook, Warrington, England, WA5 7TN'; company status Active; type Private limited Company; incorporated on 21 December 2012; nature of business (SIC) '32500 - Manufacture of medical and dental instruments and supplies'; last accounts made up to 31 December 2024, next accounts made up to 31 December 2025 due by 30 September 2026; last confirmation statement dated 18 December 2025. This corroborates the manufacturer's 'since 2012' claim and confirms a real UK manufacturing entity at the Warrington address that appears on all four FDA submissions and the MHRA record. SCOPE LIMIT: Companies House does not verify trading activity, manufacturing location, or any product claim; the page carries the standard notice that 'Companies House does not check the accuracy of the information filed'.
  7. Medicines and Healthcare products Regulatory Agency. Regulating medical devices in the UK. GOV.UK. Last updated 20 February 2026. Accessed 1 August 2026.Tier 1Supports: Establishes the GB market-access framework. CE marking remains accepted on the Great Britain market on defined timelines: devices certified under the EU MDD/AIMDD 'up until the sooner of expiry of certificate or 30 June 2028'; IVDs under the EU IVDD 'up until the sooner of expiry of certificate or 30 June 2030'; devices under EU MDR/IVDR 'up until 30 June 2030'. Government has announced it will 'consult on indefinite recognition of CE marked medical devices'. UKCA 'is a UK product marking used for certain goods, including medical devices, being placed on the Great Britain market' and 'is not recognised in the EU, EEA or Northern Ireland markets'. Registration duty: 'all medical devices, including IVDs, custom-made devices and systems or procedure packs, need to be registered with the MHRA before they are placed on the Great Britain market.' Non-UK manufacturers must appoint a UK Responsible Person. SCOPE LIMIT: this is general framework guidance; it makes no statement about Dermalux specifically.
  8. Aesthetic Technology Ltd. Dermalux professional website: product pages for Tri-Wave MD, Flex MD and Compact Lite. Accessed 1 August 2026.Tier 4Supports: CURRENT PROFESSIONAL RANGE (three devices, verified from site navigation and product pages): Tri-Wave MD, Compact Lite, Flex MD. No product called 'Visible Red' appears anywhere in the current range. TRI-WAVE MD tech spec verbatim: 'Wavelengths (+/-2nm):415nm, 633nm, 830nm', 'Classification Medical Device Class IIa', 'Treatment time (mins) 1-20', 'Dose range (joules) 8-240 j/cm2', 'Intensity (m/w) 7 - 200 mw/cm2', weight 75kg. FLEX MD: 'Wavelengths (+/- 2nm):415nm, 633nm, 830nm', 'Classification Class IIA Medical Device', 'Treatment time (mins) 1-30', 'Dose range (joules) 10-40 j/cm2', 'Intensity (m/w) 5 - 27 mw/cm2', weight 7kg, described as 'Professional and home use'. COMPACT LITE: 'Classification Electrical Device (Non-Medial [sic])', 'Treatment time (mins) 1-20', 'Dose range (joules) 7-140 j/cm2', 'Intensity (m/w) 7 - 116 mw/cm2', weight 39kg, and verbatim: 'Compact Lite is an electrical (non-medical) device non-medical device and is not covered within the scope of CE 2797.' THE CENTRAL DISCLOSURE — both medical devices list indications ('The Tri-Wave MD is certified and clinically proven to treat the following indications: Ageing Skin, Acne (Moderate to Severe, Grade 2 to 3), Inflammation skin conditions, Redness, Pigmentation, Wound Healing, Pain Management (Musculoskeletal)') and then immediately footnote, verbatim for Tri-Wave MD: 'Ageing Skin, Inflammatory Skin, Skin Tone and Redness are not covered within the scope of CE 2797', and for Flex MD: 'Ageing Skin, Inflammatory Skin, Pigmentation and Redness are not covered within the scope of CE 2797.' Tri-Wave MD page also states: 'The Tri-Wave MD is able to deliver Photodynamic Therapy (PDT) for non-melanoma skin cancers in accordance with the prodrug manufacturer guidelines.' Manufacturing claim: 'Every Dermalux device is designed, engineered and manufactured in the United Kingdom at our Warrington facility.' Evidence claims: 'Every claim is substantiated by peer-reviewed research and real clinical results' and 'independently validated'. The 'LED Explained' page claims for Blue 415nm: 'Treats All Grades Of Acne', 'Targets Certain Viruses', 'Mood Enhancing Benefits'. Site-wide badges: 'FDA Cleared Medical Device Manufacturer', 'European Design Awards Winner 2024', 'Made in Britain'. Before/after gallery entries are single-clinic anecdotes, several annotated 'Results achieved as part of a combination protocol'.Funding / interest: Manufacturer's own marketing material. Aesthetic Technology Ltd has a direct and total commercial interest in every claim on these pages.
  9. García PN, Andrino RL. Feasibility and Safety of Using Combined Light-Emitting Diodes Versus Intense Pulsed Light Technology for the Improvement of Facial Hypervascularization in Adult Patients. Photobiomodul Photomed Laser Surg. 2023 Feb;41(2):64-72. doi:10.1089/photob.2022.0079. PMID: 36780573.Tier 3Supports: THE ONLY PubMed-indexed clinical study naming a Dermalux device. Design verbatim: 'single-center, proof-of-concept, open-label, and prospective design' — NOT randomised, NOT blinded, NOT placebo-controlled. n=20 total, 10 per group, 50% female. LED-Group mean age 32.1 years (range 21-46); IPL-Group mean age 34.5 (range 25-49). Intervention: 'Dermalux Tri-Wave MD' using 'an LED device combining 633 and 830 nm' versus IPL (555-950 and 530-750 nm). Outcomes: haemoglobin hyperconcentration (HH), haemoglobin-affected area (HAA) via Antera 3D, and Numeric Pain Rating Scale. RESULTS VERBATIM — efficacy: 'HH: LED-Group 100% had a moderate improvement; in the IPL-Group, 10% was moderate, and 90% was marked. HAA: LED-Group 10% had a slight improvement, 70% moderate, and 20% marked; in the IPL-Group, 100%, the improvement was marked.' Tolerability: 'Seventy percent of LED-Group patients reported no pain, 30% mild; in the IPL-Group, 100% of patients reported severe pain.' Authors' conclusion verbatim: 'Treatment with combined red and near-infrared LEDs effectively reduced the excess of facial vascularization with moderate outcomes compared with IPL, but without secondary effects and no pain.' HONEST READING: the Dermalux arm did produce improvement in every patient, and was dramatically better tolerated — but it was clearly LESS effective than IPL on both efficacy measures. SCOPE LIMITS: n=10 per arm; no randomisation; no blinding; no control arm; no session count, irradiance, dose or follow-up duration reported in the abstract or accessible publisher text; outcome categories ('slight/moderate/marked') are ordinal investigator judgements; facial hypervascularisation only — this says nothing about acne, ageing, wound healing or pain.Funding / interest: Funding and conflict-of-interest declarations are not present in the accessible abstract or publisher record. Both authors are affiliated with Elite Laser Clinic, Madrid, a commercial private clinic. Whether Aesthetic Technology Ltd supported the study is unknown; its independence remains unestablished.
  10. Barbaric J, Abbott R, Posadzki P, Car M, Gunn LH, Layton AM, Majeed A, Car J. Light therapies for acne. Cochrane Database Syst Rev. 2016 Sep 27;9(9):CD007917. doi:10.1002/14651858.CD007917.pub2. PMID: 27670126; PMCID: PMC6457763.Tier 1Supports: The highest-tier evidence on light therapy for acne — the indication for which Dermalux's 415nm blue is actually certified. 71 studies, 4,211 participants randomised. Median study size 31 participants. Notably: 'Two thirds of studies were industry-sponsored; study authors either reported conflict of interest, or such information was not declared, so we judged the risk of bias as unclear.' For the primary outcome 'Participant's global assessment of improvement', the review 'did not combine the effect estimates but rated the quality of the evidence as very low'. AUTHORS' CONCLUSIONS VERBATIM: 'High-quality evidence on the use of light therapies for people with acne is lacking. There is low certainty of the usefulness of MAL-PDT (red light) or ALA-PDT (blue light) as standard therapies for people with moderate to severe acne.' Also: 'less than half of the studies performed assessments later than eight weeks after final treatment' — i.e. durability is largely unstudied. Adverse-effect evidence rated 'very low' quality. SCOPE LIMITS: search to September 2015 (updated July 2016, not incorporated), so it predates the current Dermalux range; it concerns light therapies for acne generally and assesses NO Dermalux device; much of its analysis concerns photodynamic therapy with ALA/MAL rather than standalone LED.Funding / interest: Cochrane review. COI statement read in full: most authors declare nothing. Alison M Layton declares extensive pharmaceutical industry relationships (Galderma, GlaxoSmithKline, MEDA, LeoPharma, Valeant, Dermira, Pfizer, Novartis, Wyeth, L'Oreal) for research grants, lecturing honoraria and advisory work, stating 'I am not affiliated to or hold shares in any one specific company.' Two external peer-reviewers (Sanclemente, Dreno) declare Galderma relationships. No LED-device-manufacturer funding.
  11. Russell BA, Kellett N, Reilly LR. A study to determine the efficacy of combination LED light therapy (633 nm and 830 nm) in facial skin rejuvenation. J Cosmet Laser Ther. 2005 Dec;7(3-4):196-200. doi:10.1080/14764170500370059. PMID: 16414908.Tier 3Supports: INCLUDED BECAUSE IT IS THE SOURCE OF THE PARAMETERS, NOT OF DERMALUX EVIDENCE. This is the foundational red+NIR LED rejuvenation study. Design: 31 subjects with facial rhytids, nine treatments, uncontrolled and unblinded. Intervention verbatim: 'Thirty-one subjects with facial rhytids received nine light therapy treatments using the Omnilux LED system. The treatments combined wavelengths of 633 nm and 830 nm with fluences of 126 J/cm(2) and 66 J/cm(2) respectively.' Results verbatim: 'Key profilometry results Sq, Sa, Sp and St showed significant differences at week 12 follow-up; 52% of subjects showed a 25%-50% improvement in photoaging scores by week 12; 81% of subjects reported a significant improvement in periorbital wrinkles on completion of follow-up.' CRITICAL CROSS-REFERENCE: the Dermalux Tri-Wave MD's FDA-declared standard doses (source 1) are Red 633nm = 126 J/cm2 and NIR 830nm = 66 J/cm2 — numerically IDENTICAL to the Omnilux fluences used here. SCOPE LIMITS: this is an Omnilux device, NOT a Dermalux device; n=31; no control group; no randomisation; no blinding; 12-week follow-up only; profilometry on periorbital casts plus subjective scores.Funding / interest: No funding or COI statement available in the PubMed record. The study evaluates the Omnilux system; lead author affiliation 'Advanced Laser and Dermatologic Surgery Clinics PC, Beaverton, Oregon'. Commercial relationship to Omnilux not disclosed in the accessible record — treat independence as unestablished.
  12. British Medical Laser Association. BMLA 2022 Annual Conference — abstract book. Published in Lasers Med Sci / BMLA proceedings, 2022. PMCID: PMC9427434. PMID: 36044122.Tier 4Supports: Full text searched for every 'Dermalux' mention. TWO relevant abstracts. (1) SS.05 'Next generation medical LED phototherapy - clinical advantages', Mr Dale Needham, Aesthetic Technology Ltd — biography verbatim: 'Dale Needham, Managing Director of Aesthetic Technology Ltd who manufacture the Dermalux LED system, is a global authority in LED design and engineering.' This is a manufacturer presentation at a professional conference, not independent evidence; it is included to show how Dermalux's authority position is built. (2) SS.06 'The role of LED phototherapy to assist laser treatments for hidrenitis supporotiva [sic]', Mrs Roxana Chiru, Professor Sandip Hindocha, Sr Kerry Muggesson, Bedford Hospital NHS Trust — the only UK NHS clinical report located. Verbatim: 'The plastic surgery and laser centre at Bedford Hospital has been introduced to LED phototherapy (MD tri-wave light, Dermalux)... We have recently trialled this product as an adjunct to surgical excision and alongside lasers in aid to promote healing along the proliferative and remodelling phases of wound healing. We have seen that there is sufficient improvement in the clinical state of the wound.' SCOPE LIMITS: a conference abstract, not a peer-reviewed paper. No patient numbers, no control group, no outcome measure, no statistics, no follow-up — 'sufficient improvement' is the entire reported result. This cannot support an efficacy claim for hidradenitis suppurativa; it establishes only that a UK NHS unit has used the device adjunctively and reported a favourable impression.Funding / interest: Mixed. One cited abstract (SS.05) is delivered by the Dermalux manufacturer's own Managing Director — a direct commercial interest. The other (SS.06) is from NHS clinicians with no declared device interest, though the device was supplied to their unit.
  13. Osipowicz K, Turkowski P, Kowalewski C, Pach J, Regulski P, Wozniak K. Hair Transplantation for Lichen Planopilaris: A Case Series of Five Patients. J Clin Med. 2025 Sep 2;14(17):6199. doi:10.3390/jcm14176199. PMID: 40943957; PMCID: PMC12428977.Tier 3Supports: Located by full-text search of Europe PMC for 'Dermalux'. The device appears only in the surgical methods, verbatim: 'After the procedure, the scalp was irradiated with a Tri-Wave LED lamp (Dermalux, Warrington, UK) to accelerate healing.' SCOPE LIMITS — this supports essentially nothing about Dermalux efficacy: n=5 case series, no control, the LED was one component of a multi-part protocol also involving PRP and hair transplantation, no LED-specific outcome was measured, no LED parameters (dose, duration, number of sessions) are reported, and no comparison with or without LED was made. It is included ONLY as an honest illustration of how Dermalux actually appears in the peer-reviewed literature: as an incidental adjunct in someone else's procedure, never as the studied intervention. It also independently corroborates the Warrington manufacturing base.Funding / interest: The article states that it received no external funding and that the authors declare no conflicts of interest.
  14. Committee of Advertising Practice / Advertising Standards Authority. Advice Online: Health — Phototherapy. asa.org.uk. Accessed 1 August 2026.Tier 1Supports: CAP's Advice Online page 'Health: Phototherapy', dated 15 January 2021, says products intended to treat a medical condition may fall within the medical-device regime and advises consulting the MHRA. Its statement that the ASA is likely to expect robust clinical evidence is specifically framed around claims to treat seasonal affective disorder or its symptoms. The page also states more generally: 'Marketers are reminded that they would also need to hold clinical evidence for any other advertising claims about the benefits of Phototherapy.' Its rule 12.2 example concerns discouraging essential treatment through a lack of suitably qualified supervision. Scope limits: this is general CAP guidance, not a Dermalux-specific ruling; its worked examples concern SAD lamps and sunbeds.